StockNews.com initiated coverage on shares of NanoViricides (NYSE:NNVC – Free Report) in a research note issued to investors on Friday morning. The firm issued a sell rating on the stock.
NanoViricides Stock Down 7.2 %
NanoViricides stock traded down $0.16 during midday trading on Friday, hitting $2.07. The stock had a trading volume of 223,122 shares, compared to its average volume of 251,338. The business has a fifty day moving average price of $1.33 and a 200 day moving average price of $1.21. NanoViricides has a 12 month low of $1.00 and a 12 month high of $2.29.
NanoViricides (NYSE:NNVC – Get Free Report) last posted its quarterly earnings results on Wednesday, February 14th. The company reported ($0.18) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.19) by $0.01.
About NanoViricides
NanoViricides, Inc, a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company's product portfolio includes NV-CoV-2, nanoviricide drug which is in phase 1a/1b clinical trails for the treatment of Covid; and NV-CoV-2 Oral Syrup, and NV-CoV-2 Oral Gummies, a semi-solid fixed-dose form which are in phase 1a/1b human clinical trials for enabling body-weight-based dose titration as is required for pediatric cases.
Featured Stories
- Five stocks we like better than NanoViricides
- How to Calculate Return on Investment (ROI)
- MarketBeat Week in Review – 5/13 – 5/17
- Stocks with Unusual Volume: How to Find Unusual Volume Stocks in Real Time
- Take-Two Interactive Software Offers 2nd Chance for Investors
- There Are Different Types of Stock To Invest In
- Deere & Company’s Q2 Report: Strong Revenue, Cautious Outlook
Receive News & Ratings for NanoViricides Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NanoViricides and related companies with MarketBeat.com's FREE daily email newsletter.
